Posted on 23/10/2009 in Pharmaceutical Company Financials UCB has reported its financial results for the first nine months of 2009, which, according to the firm, are in line with its previous expectations.
Its revenue declined compared to the same period in 2008, something that UCB attributes to generic competition to Keppra (levetiracetam) in the US.
However, it added, this was partially offset by the strong performance of Keppra in Europe, as the drug continued to show double-digit percentage net sales growth on the continent.
Additionally, the strong growth of Xyzal (levocetirizine) in the US and of Zyrtec (cetirizine) in Japan also boosted its sales.
Roch Doliveux, the chief executive of UCB, stated: "While it is still early in the launch roll-out of our major new products Cimzia, Vimpat and Neupro, we are pleased with trends in prescription uptake."
In other UCB news, the organisation revealed earlier this month that its rheumatoid arthritis therapy Cimzia (certolizumab pegol) has been approved by the European commission.
Other news stories from 23/10/2009
Read more in the Zenopa News Archive
How this news is generated
|
